Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 787.37

+3.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Ox who wrote (1887)	4/1/2016 1:54:43 PM
From: Miljenko Zuanic	of 3559

<<As to valuations and which specific drug or testing program is going to be seen as "worth more" down the road...>> It is not that hard, bit of the efforts and luck! For instance, good safety of SOLO1/2 set the stage for two more significant D-indications: Pediatric AD and Asthma, in addition to EoE and Nosal P. This at least double market opportunity, and IF they "discover" additional allergic-indications..Dupilumab may become true $$$B-drug. Problem with REGN is that their HUMAN-Ab are not rely true h-Ab, only 2 weeks of efficacy (they NEED 4 or even 8 WEEKS of drug action). This may become true problem down the road, because CONVENIENCE and DRUG PRICE will be IMPORTANT!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next